<DOC>
	<DOCNO>NCT00781378</DOCNO>
	<brief_summary>Recombinant tissue plasminogen activator ( rt-PA ) currently commonly use thrombolytic drug patient pulmonary thromboembolism ( PTE ) . Optimal dose maximal benefit minimal risk great importance . Considering low body weight general Chinese population , compare efficacy safety low dose rt-PA 50mg/2h regimen FDA-approved rt-PA 100mg/2h regimen select PTE patient .</brief_summary>
	<brief_title>Low Dosage rt-PA Treatment Pulmonary Thromboembolism China</brief_title>
	<detailed_description>Pulmonary thromboembolism ( PTE ) severe common clinical problem substantial morbidity mortality US Europe . Used consider rare disease China , PTE increasingly diagnose recent year due increase awareness improvement image technique . PTE life threaten without proper intervention early onset . Effective treatment decrease mortality complication chronic thromboembolic pulmonary hypertension ( CTEPH ) . Recombinant tissue-type plasminogen activator ( rt-PA ) currently commonly use drug PTE thrombolysis . Like thrombolytic medication , rt-PA carry risk significant bleeding , dose dependent . Thus , optimal dose maximize benefit minimize risk great importance . There substantial controversy debate regard optimal rt-PA dosage thrombolytic therapy whether dose use patient . Low dose intravenous rt-PA thrombolysis acute myocardial infarction ( AMI ) suggest previous study . Experimental clinical study indicate low dose rt-PA bolus may potentially safer , yet equally effective 2-h 100 mg rt-PA continuous infusion PTE . Considering low body weight Chinese population , low dose 50mg rt-PA/2h may exhibit similar efficacy safety 100mg/2-h rt-PA treat acute PTE population . We , therefore , compare two regimen multi-center , randomize , control trial . The efficacy assess improvement right ventricular function echocardiogram , perfusion defect score lung V/Q scan quantitative compute tomographic ( CT ) evaluation , safety evaluate incidence major minor bleeding , death rate , PTE recurrence 24h,14d treatment . 110 patient randomize study . The patient include study randomize , double blind fashion , receive rt-PA 100mg 2h ( 55 patient ) rt-PA50mg 2h ( 55 patient ) .Study treatment administer within 72 hour echocardiography . Echocardiography repeat 24 hour 14 day rt-PA injection . A Follow-up visit 14 day randomization include : clinical history , physical examination ECG echocardiographic examination CTPA V/Q scan .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>age 18 75 symptomatic PE confirm : high probability ventilationperfusion lung scanning ( V/Q scan ) presence intraluminal filling defect spiral compute tomographic pulmonary angiography ( CTPA ) PTE patient haemodynamic instability , cardiogenic shock anatomic obstruction 2 lobe CTPA , defect 7 segment V/Q scan combine evidence right ventricular dysfunction ( RVD ) pulmonary hypertension echocardiography write informed consent active bleeding spontaneous intracranial hemorrhage major surgery , organ biopsy recent puncture noncompressible vessel le 10 day cerebral arterial thrombosis within 2 month gastrointestinal bleeding within 10 day major trauma within past 15 day neurosurgery ophthalmologic operation 30 day uncontrolled hypertension ( systolic blood pressure &gt; 180 mmHg and/or diastolic blood pressure &gt; 110 mmHg ) recent external cardiac resuscitation manoeuvre platelet count &lt; 100 000/mm3 admission pregnancy , puerperium lactation 2 week infectious pericarditis endocarditis severe hepatic kidney dysfunction hemorrhagic retinopathy due diabetes known bleeding disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Thrombolytic therapy</keyword>
	<keyword>Recombinant tissue plasminogen activator</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>